<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/B2EE12FB-8E49-4F6A-8073-DF35FAF50581"><gtr:id>B2EE12FB-8E49-4F6A-8073-DF35FAF50581</gtr:id><gtr:name>Emory University</gtr:name><gtr:address><gtr:line1>201 Dowman Drive</gtr:line1><gtr:line4>Atlanta</gtr:line4><gtr:line5>Ga 30322</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/62B693D8-12F4-4EEE-A622-010188252868"><gtr:id>62B693D8-12F4-4EEE-A622-010188252868</gtr:id><gtr:name>North Bristol NHS Trust</gtr:name><gtr:address><gtr:line1>Trust Headquarters</gtr:line1><gtr:line2>Frenchay Hospital</gtr:line2><gtr:line3>Beckspool Road, Frenchay</gtr:line3><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS16 1JE</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/62B693D8-12F4-4EEE-A622-010188252868"><gtr:id>62B693D8-12F4-4EEE-A622-010188252868</gtr:id><gtr:name>North Bristol NHS Trust</gtr:name><gtr:address><gtr:line1>Trust Headquarters</gtr:line1><gtr:line2>Frenchay Hospital</gtr:line2><gtr:line3>Beckspool Road, Frenchay</gtr:line3><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS16 1JE</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9"><gtr:id>3EAE04CA-9D62-4483-B9C4-F91AD9F4C5A9</gtr:id><gtr:name>University of Oxford</gtr:name><gtr:address><gtr:line1>University Chest</gtr:line1><gtr:line2>Wellington Square</gtr:line2><gtr:line4>Oxford</gtr:line4><gtr:postCode>OX1 2JD</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/30A429E3-83B7-4E41-99C0-14A144F07DFE"><gtr:id>30A429E3-83B7-4E41-99C0-14A144F07DFE</gtr:id><gtr:name>University of Southampton</gtr:name><gtr:address><gtr:line1>Administration Building</gtr:line1><gtr:line2>Highfield</gtr:line2><gtr:line4>Southampton</gtr:line4><gtr:line5>Hampshire</gtr:line5><gtr:postCode>SO17 1BJ</gtr:postCode><gtr:region>South East</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EC23DA53-CA73-4104-A3F6-2A9523484E69"><gtr:id>EC23DA53-CA73-4104-A3F6-2A9523484E69</gtr:id><gtr:name>Queen's University of Belfast</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Belfast</gtr:line4><gtr:line5>County Antrim</gtr:line5><gtr:postCode>BT7 1NN</gtr:postCode><gtr:region>Northern Ireland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B2EE12FB-8E49-4F6A-8073-DF35FAF50581"><gtr:id>B2EE12FB-8E49-4F6A-8073-DF35FAF50581</gtr:id><gtr:name>Emory University</gtr:name><gtr:address><gtr:line1>201 Dowman Drive</gtr:line1><gtr:line4>Atlanta</gtr:line4><gtr:line5>Ga 30322</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>United States</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/318B5D98-4CB4-4B10-A876-08FC93071A56"><gtr:id>318B5D98-4CB4-4B10-A876-08FC93071A56</gtr:id><gtr:name>King's College London</gtr:name><gtr:address><gtr:line1>Capital House</gtr:line1><gtr:line2>2nd Floor, Guys Campus</gtr:line2><gtr:line3>42 Weston Street</gtr:line3><gtr:line4>London</gtr:line4><gtr:postCode>SE1 3QD</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/5F1BF1A5-2175-4D08-8EEE-FAA4EEA64CC8"><gtr:id>5F1BF1A5-2175-4D08-8EEE-FAA4EEA64CC8</gtr:id><gtr:firstName>Patrick</gtr:firstName><gtr:otherNames>Gavin</gtr:otherNames><gtr:surname>Kehoe</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MC_PC_13088"><gtr:id>21F34BAB-F72D-436C-8B46-2CC529E4C93C</gtr:id><gtr:title>Reducing pathology in Alzheimer?s Disease through Angiotensin TaRgeting - The RADAR Trial</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Intramural</gtr:grantCategory><gtr:grantReference>MC_PC_13088</gtr:grantReference><gtr:abstractText>Alzheimer?s disease (AD) profoundly affects memory and brain function in older individuals. It is a slow progressive disease which can last for a number of years - a heart-breaking, exhausting and often costly reality for family and health services. With an ageing population, AD health care provision needs will significantly rise. Existing treatments only temporarily treat specific imbalances in the brain but as yet there is no cure for AD. We will undertake a clinical trial at Bristol (in collaboration with University College London (UCL)) to see if losartan, a well tolerated blood pressure drug, can complement current treatments for AD. We believe losartan will slow down the progression of AD by improving brain blood flow and altering chemical pathways that cause brain cell damage, brain shrinkage and memory problems in AD. This study will use brain imaging to measure if losartan reduces brain shrinkage which is already known to be strongly linked with reduced memory function. We will also investigate if losartan alters the profile and activity of various blood-borne proteins which may be predictive of rates of disease progression. We want to study losartan because human and animal studies tell us reduced brain blood flow is a very common and early feature in AD and contributes to memory failure. Losartan blocks a chemical pathway (angiotensin II) to improve memory problems in mice designed to have Alzheimer?s features and in people given chemicals to temporarily affect their memories. Losartan is thought to stop angiotensin II from preventing the release of vital memory chemicals in the brain. We recently found that people who have previously taken losartan, or similar drugs, have lower risk of developing AD compared to other blood pressure drugs. These drugs also slow the rate of deterioration in patients with Alzheimer?s. However clinical trials of losartan and related drugs in people with high blood pressure have shown little evidence of a reduced risk of cognitive decline or dementia in general. These studies however did not include or specifically identify AD patients and would have had many patients with mainly vascular dementia patients which have not benefited. There are no major ethical issues in this study. It may also appear costly for a small study, but it uses expensive surrogate markers of disease that can be studied in a shorter time. RADAR will offer great value for money if this cheap (3-4p per day) well tolerated drug is found to be beneficial in AD. RADAR will also provide the requisite evidence needed to justify the much larger multi-centre trial (which will use cheaper measures of disease over a longer study time) that will be needed to provide the final proof of losartan?s benefit in AD. This trial which involves leading international centres for angiotensin research in dementia (Bristol) and imaging (UCL) should provide such evidence.</gtr:abstractText><gtr:technicalSummary>Research design: A two arm blinded placebo-controlled randomised controlled trial (RCT). Study population: RADAR will study incident and prevalent cases of mild-to-moderate AD diagnosed according to revised NINCDS-ADRDA criteria. Participants can be hypertensive or normotensive and on any existing dementia drugs with no age restrictions. Inclusion requires an MMSE score of 15-24; a modified Hachinski score of 4 or less, a previous CT or MRI scan supporting a diagnosis of AD and the presence of care-giver in daily contact. Exclusion criteria include anyone already taking other renin angiotensin acting drugs or potassium diuretics; contraindications or conditions that make MRI unfeasible; a BP of &amp;lt; 120/75 mmHg, &amp;gt; 160/110 mmHg and/or postural hypotension (BP drop of &amp;gt;20/10 mmHg after 3-5 minutes); prior history of stroke or transient ischaemic attacks; unstable congestive heart failure; severe renal or hepatic impairment or a history of gout; other primary neurodegenerative or psychiatric disorders other than AD or other possible primary causes of dementia; a recent history of untreated clinically significant hypothyroidism or hyperthyroidism (patients are euthyroid and stable are eligible). Interventions: Patients will be randomised to either encapsulated 100mg generic losartan or placebo once daily for 12 months after a 1 month open label phase which establish drug tolerability. Outcomes: Primary outcome measures will be the rate of whole brain atrophy as a surrogate measure of cognitive decline. Secondary outcomes: (i) white matter hyperintensities (WMH) volume and cerebral blood flow (CBF) (also surrogate markers of cognitive decline and disease progression); (ii) performance on a standard battery of assessments of memory, cognitive function, activities of daily living and quality of life; (iii) changes to levels of plasma protein markers of AD (Abeta, acetylcholinesterase) and AngII pathway-linked AD-related markers (ACE, NEP, TNFalpha, CRP). Major assessments (for all outcomes) will be at baseline and 12 months while an added interim 6 month visit will include cognitive assessments only. Safety monitoring for blood pressure and side effects will occur at weekly intervals of the open-label phase and at 14 days, 3, 6 and 9 months post-randomisation. Based on recent studies conducted within ADNI to optimise protocols for imaging use in clinical trials of AD, we will recruit a sample size of 228 participants (recruited over 15 months) to provide at least 182 subjects with final assessments to provide 84% power to detect a 25% difference in atrophy rate (therapeutic benefit) change over 12 months at an alpha level of 0.05. We will use intention-to-treat analysis to measure our outcomes, measuring between-group estimates of effectiveness derived from appropriate (linear or logistic) multivariable regression models adjusting for minimisation variables and value of outcome at baseline and at the end of the study (12 month follow-up for all primary and secondary outcomes) and for the 6 month cognitive assessment data.</gtr:technicalSummary><gtr:fund><gtr:end>2018-02-28</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2013-03-01</gtr:start><gtr:type>EXPENDITURE_ACTUAL</gtr:type><gtr:valuePounds>800092</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Nottingham</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Nottingham Clinical Trials Unit (NCTU)</gtr:department><gtr:description>AFFECT Trial (Commenced but then terminated due to funding issues)</gtr:description><gtr:id>5B4905E5-E57F-4CF4-8744-04088067F607</gtr:id><gtr:impact>Protocol paper published in Trials: https://www.ncbi.nlm.nih.gov/pubmed/27430267 entitled: A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol.</gtr:impact><gtr:outcomeId>QbB2P3soLTn-4</gtr:outcomeId><gtr:partnerContribution>This project is being led by Queen's University of Belfast and all the others are co-Investigators and will eventually lead recruitment sites.</gtr:partnerContribution><gtr:piContribution>Through my leadership on the RADAR trial and my involvement in another Alzheimer's Society funded project of Vascular Cognitive Impairment I was invited to become a co-investigator on a planned trial of amlodipine for sub-cortical ischaemic vascular dementia co-funded between BHF and Alzheimer's Society. However due to the low prevalence and heterogeneity of the condition it has a significant impact on recruitment and the study has been discontinued.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Core Outcome Data Set for Dementia clinical trials (COD Dementia)</gtr:description><gtr:id>EEBD4B32-01A9-459C-BE15-412058E0B8B5</gtr:id><gtr:impact>Work yet to be undertaken</gtr:impact><gtr:outcomeId>56de0f1f255c78.62915836-1</gtr:outcomeId><gtr:partnerContribution>The first activity on this is scheduled for April 7th and is being co-ordinated by the UCL members who are the primary leads on this project - the initiative involves almost 40 collaborators.</gtr:partnerContribution><gtr:piContribution>Resulting from a HTA/NIHR supported event this gave rise to an invitation from HTA to bid for a small amount of funds to come up with a set of 'consensus' outcome measures that could be applied to dementia clinical trials and an award was funded to the leads at UCL (HTA Project: 15/62/02).</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Psychiatry, Psychology &amp; Neuroscience</gtr:department><gtr:description>AFFECT Trial (Commenced but then terminated due to funding issues)</gtr:description><gtr:id>125EA98A-8366-4B85-BCED-9D77560A6E2D</gtr:id><gtr:impact>Protocol paper published in Trials: https://www.ncbi.nlm.nih.gov/pubmed/27430267 entitled: A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol.</gtr:impact><gtr:outcomeId>QbB2P3soLTn-6</gtr:outcomeId><gtr:partnerContribution>This project is being led by Queen's University of Belfast and all the others are co-Investigators and will eventually lead recruitment sites.</gtr:partnerContribution><gtr:piContribution>Through my leadership on the RADAR trial and my involvement in another Alzheimer's Society funded project of Vascular Cognitive Impairment I was invited to become a co-investigator on a planned trial of amlodipine for sub-cortical ischaemic vascular dementia co-funded between BHF and Alzheimer's Society. However due to the low prevalence and heterogeneity of the condition it has a significant impact on recruitment and the study has been discontinued.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Oxford</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Clinical Trial Service Unit and Epidemiological Studies Unit (CTSU)</gtr:department><gtr:description>AFFECT Trial (Commenced but then terminated due to funding issues)</gtr:description><gtr:id>9491ED90-6902-4CFC-A972-000F230B7CA7</gtr:id><gtr:impact>Protocol paper published in Trials: https://www.ncbi.nlm.nih.gov/pubmed/27430267 entitled: A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol.</gtr:impact><gtr:outcomeId>QbB2P3soLTn-5</gtr:outcomeId><gtr:partnerContribution>This project is being led by Queen's University of Belfast and all the others are co-Investigators and will eventually lead recruitment sites.</gtr:partnerContribution><gtr:piContribution>Through my leadership on the RADAR trial and my involvement in another Alzheimer's Society funded project of Vascular Cognitive Impairment I was invited to become a co-investigator on a planned trial of amlodipine for sub-cortical ischaemic vascular dementia co-funded between BHF and Alzheimer's Society. However due to the low prevalence and heterogeneity of the condition it has a significant impact on recruitment and the study has been discontinued.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Geriatric Medicine</gtr:department><gtr:description>AFFECT Trial (Commenced but then terminated due to funding issues)</gtr:description><gtr:id>C505989E-ADF8-41D0-97C8-E00613F12CB7</gtr:id><gtr:impact>Protocol paper published in Trials: https://www.ncbi.nlm.nih.gov/pubmed/27430267 entitled: A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol.</gtr:impact><gtr:outcomeId>QbB2P3soLTn-1</gtr:outcomeId><gtr:partnerContribution>This project is being led by Queen's University of Belfast and all the others are co-Investigators and will eventually lead recruitment sites.</gtr:partnerContribution><gtr:piContribution>Through my leadership on the RADAR trial and my involvement in another Alzheimer's Society funded project of Vascular Cognitive Impairment I was invited to become a co-investigator on a planned trial of amlodipine for sub-cortical ischaemic vascular dementia co-funded between BHF and Alzheimer's Society. However due to the low prevalence and heterogeneity of the condition it has a significant impact on recruitment and the study has been discontinued.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>King's College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Wolfson Centre for Age-Related Diseases</gtr:department><gtr:description>AFFECT Trial (Commenced but then terminated due to funding issues)</gtr:description><gtr:id>1C734BC8-E098-47E1-88B3-AD19CF236C89</gtr:id><gtr:impact>Protocol paper published in Trials: https://www.ncbi.nlm.nih.gov/pubmed/27430267 entitled: A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol.</gtr:impact><gtr:outcomeId>QbB2P3soLTn-2</gtr:outcomeId><gtr:partnerContribution>This project is being led by Queen's University of Belfast and all the others are co-Investigators and will eventually lead recruitment sites.</gtr:partnerContribution><gtr:piContribution>Through my leadership on the RADAR trial and my involvement in another Alzheimer's Society funded project of Vascular Cognitive Impairment I was invited to become a co-investigator on a planned trial of amlodipine for sub-cortical ischaemic vascular dementia co-funded between BHF and Alzheimer's Society. However due to the low prevalence and heterogeneity of the condition it has a significant impact on recruitment and the study has been discontinued.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Queen's University Belfast</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>Collaborative grant application</gtr:description><gtr:id>BAAD65A9-6044-46E7-906C-C3D722E6824C</gtr:id><gtr:impact>None</gtr:impact><gtr:outcomeId>5464b5996fb9d0.35567977-1</gtr:outcomeId><gtr:partnerContribution>Led by colleagues in Belfast with specific expertise in retinal imaging that we can test its application in certain clinical trial approaches.</gtr:partnerContribution><gtr:piContribution>An MRC DPFS application was submitted and re-invited subject to some changes.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2014-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Southampton</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Psychiatry</gtr:department><gtr:description>AFFECT Trial (Commenced but then terminated due to funding issues)</gtr:description><gtr:id>EFFB516C-7954-4AD5-AD6B-9A7EC2F8A4D1</gtr:id><gtr:impact>Protocol paper published in Trials: https://www.ncbi.nlm.nih.gov/pubmed/27430267 entitled: A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol.</gtr:impact><gtr:outcomeId>QbB2P3soLTn-3</gtr:outcomeId><gtr:partnerContribution>This project is being led by Queen's University of Belfast and all the others are co-Investigators and will eventually lead recruitment sites.</gtr:partnerContribution><gtr:piContribution>Through my leadership on the RADAR trial and my involvement in another Alzheimer's Society funded project of Vascular Cognitive Impairment I was invited to become a co-investigator on a planned trial of amlodipine for sub-cortical ischaemic vascular dementia co-funded between BHF and Alzheimer's Society. However due to the low prevalence and heterogeneity of the condition it has a significant impact on recruitment and the study has been discontinued.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Emory University</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>Health Evaluation in African Americans using RAS Therapy: The HEART Project.</gtr:description><gtr:id>FD4A0731-7585-4653-BB8F-7FD5F8ECA5A0</gtr:id><gtr:impact>Work just getting underway and protocol just been finalised.</gtr:impact><gtr:outcomeId>56de1195507eb7.27924726-1</gtr:outcomeId><gtr:partnerContribution>The majority of the work was led in this in terms of protocol development and the funding application to the Alzheimer's Association in the US that I am listed as a collaborator on.</gtr:partnerContribution><gtr:piContribution>I was invited to contribute to this study to evaluate the potential benefit of using a specific blood pressure drug, related to that in the RADAR Trial in relation to an ethnic minority group with a view to designing future studies for Alzheimer's disease and Mild Cognitive Impairment.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Invited Lecture to the Cardiff School of Pharmacy</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>A4A908A6-CA83-4C85-9346-50AB665E1362</gtr:id><gtr:impact>Introduction to new theories around molecular mechanisms of cerebrovascular disease as an introduction to the currently funded study.</gtr:impact><gtr:outcomeId>58c1635447eaa3.16748203</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Undergraduate students</gtr:primaryAudience><gtr:year>2017</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Together for dementia - Behind the headlines</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E7A2B722-E31F-4135-A3FB-68B94DD83F56</gtr:id><gtr:impact>&amp;quot;Together for Dementia&amp;quot; brought together people with diverse perspectives on dementia - researchers, clinicians, carers, care home managers, campaigners, designers, policy makers and, of course, people who themselves are living with dementia. Intended to provide a forum to help people learn about and discuss various aspects of dementia.</gtr:impact><gtr:outcomeId>56de14e21dfdf6.27431587</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.alzheimers-brace.org/events/brace-dementia-conference</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>6BE82926-D435-468B-A345-2C8D094B6905</gtr:id><gtr:impact>Had interested people seeking more information on the study

Was invited to join an outline application for another clinical trial in Alzheimer's disease.</gtr:impact><gtr:outcomeId>5464b07d403de1.75471113</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.alzheimers.org.uk/site/scripts/documents_info.php?documentID=2697</gtr:url><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Alzheimer's Research UK Public Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>C4002DD2-BB66-4184-BBD1-6E8664A3FC00</gtr:id><gtr:impact>Between 80-150 people attend every year.
The speakers vary annually and represent the researchers local to the Centre.

There is an active mailing list who remain engaged and are returning year on year.</gtr:impact><gtr:outcomeId>SndpHNypNBu</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>Pre-2006,2006,2007,2008,</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Plenary Lecture</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>B6A620E2-6BA7-4CD3-8133-1346CB396280</gtr:id><gtr:impact>Stimulating discussion afterwards with a number of academics

Some new collaborations have been discussed.</gtr:impact><gtr:outcomeId>5464b27d8212b8.01509561</gtr:outcomeId><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>RADAR funding announcement radio Interview</gtr:description><gtr:form>A formal working group, expert panel or dialogue</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>BA9CCA8F-477D-4313-9617-C58C8215AD8B</gtr:id><gtr:impact>A radio interview on BBC Bristol following the announcement of funding for the RADAR trial and it receiving front page news in National Newspapers.

We received a number of approaches from patients and carers requesting to participate in the trial.</gtr:impact><gtr:outcomeId>kAxTwVmqC54</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Invited Lecture to Vas-Cog 2016</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>BADF1A4A-BD07-49A0-879D-E5F7C616AD8E</gtr:id><gtr:impact>A specialised session presenting new intervention strategies for diseases that include cerebrovascular dysfunction wherein my talk proposed new pathways and introduced our current study funded.</gtr:impact><gtr:outcomeId>58c162a669bf55.27534733</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Dementia HIT Clinical Research Showcase</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>F116B18A-CA8A-40DD-ADD0-F15DC8566924</gtr:id><gtr:impact>An event showcase some of the portfolio of clinical dementia-related research going on in the greater Bristol area.</gtr:impact><gtr:outcomeId>56de1811614673.39051417</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.eventbrite.co.uk/e/dementia-hit-clinical-research-showcase-tickets-19378160600#</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>&quot;Lift your memory by lowering your blood pressure: The Radar Trial&quot;</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>E1D26A2D-B108-4F6C-B150-0EC16144000D</gtr:id><gtr:impact>Attendees had the opportunity to meet with leading researchers from across the region and listen to 10-minute talks about their research projects.</gtr:impact><gtr:outcomeId>56de13e351f987.09838136</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.eventbrite.co.uk/e/forgetwest-find-out-about-dementia-research-get-involved-west-of-england-tickets-15454291201#</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>150143</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Perros Trust PhD Scholarship</gtr:description><gtr:end>2018-08-02</gtr:end><gtr:fundingOrg>Perros Trust</gtr:fundingOrg><gtr:id>A7B62C91-3A50-4F48-8560-7E4CE043FBE9</gtr:id><gtr:outcomeId>58c167ade90094.80357050</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>150000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Bristol Alumni</gtr:description><gtr:end>2018-03-02</gtr:end><gtr:fundingOrg>Perros Trust</gtr:fundingOrg><gtr:id>87E315BF-BBD9-4DFE-953B-B6065355090E</gtr:id><gtr:outcomeId>5464ad41c8dcd0.51522191</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>300000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>USD</gtr:currCode><gtr:currCountryCode>Ecuador</gtr:currCountryCode><gtr:currLang>es_EC</gtr:currLang><gtr:description>Proof of Concept Award</gtr:description><gtr:end>2019-08-02</gtr:end><gtr:fundingOrg>BrightFocus Foundation</gtr:fundingOrg><gtr:id>895071A6-0E06-4234-8E6D-2058E6EF1790</gtr:id><gtr:outcomeId>58c160be1ca314.68807774</gtr:outcomeId><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>50000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>University of Bristol Alumni</gtr:description><gtr:end>2014-03-02</gtr:end><gtr:fundingOrg>University of Bristol</gtr:fundingOrg><gtr:id>4F43F327-87CE-4868-9722-51A782E5B715</gtr:id><gtr:outcomeId>YE7Kc5rVtXY</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-03-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs><gtr:productOutput><gtr:description>DIZE is an ACE2 enhancer compound, originally developed as a possible treatment for hypertension but which we are currently undertaking proof of concept work on with a view to its scope for repurposing in Alzheimer's disease.</gtr:description><gtr:id>22A1517F-4854-4877-8508-570812FB0C5D</gtr:id><gtr:impact>If the proof of concept work is positive - then there will be scope to immediately test in humans, given that the compound has been available for a number of years to treat some difficult tropical diseases of the CNS.</gtr:impact><gtr:outcomeId>58c16586d625f3.04143991</gtr:outcomeId><gtr:stage>Refinement.  Non-clinical</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>DIZE</gtr:title><gtr:type>Therapeutic Intervention - Drug</gtr:type><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>This is a database developed for the collection and storage of data being collected over the course of the trial. It is intended to be accessible by all participating sites for the upload of data remotely to expedite data entry and collection for the study as a whole.</gtr:description><gtr:id>47B3097B-AC02-4024-A3BA-48A287CAA56D</gtr:id><gtr:impact>This system will enable data entry and collection across the multiple sites available in the RADAR Trial and provide a mechanism by which data can then be exported both for analysis in due course, for auditing purposes and for monitoring e.g. via DMEC for the trial.</gtr:impact><gtr:outcomeId>56de194c8238f3.46577986</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>RADAR Clinical Database</gtr:title><gtr:type>Database/Collection of data</gtr:type></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>B7A0E0B2-01B9-4EF9-A59D-749B806CD2A0</gtr:id><gtr:title>Rationale and Design of the Mechanistic Potential of Antihypertensives in Preclinical Alzheimer's (HEART) Trial.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ce032b48cb01a7a67c62367cbc5b591e"><gtr:id>ce032b48cb01a7a67c62367cbc5b591e</gtr:id><gtr:otherNames>Wharton W</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>5a9d236a023158.48138221</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9E831EDB-DE93-4696-A436-D73DA80B757C</gtr:id><gtr:title>A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol.</gtr:title><gtr:parentPublicationTitle>Trials</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4abdaeb8963c908d6294c545beb41494"><gtr:id>4abdaeb8963c908d6294c545beb41494</gtr:id><gtr:otherNames>Greenan C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1745-6215</gtr:issn><gtr:outcomeId>5a9d25ec840970.17953780</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F3AA6388-105A-4D0E-9BF3-1CD8C169A205</gtr:id><gtr:title>Effects of Hypertension and Anti-Hypertensive Treatment on Amyloid-? (A?) Plaque Load and A?-Synthesizing and A?-Degrading Enzymes in Frontal Cortex.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/921deaa2b9f4de4187f1b665baf59712"><gtr:id>921deaa2b9f4de4187f1b665baf59712</gtr:id><gtr:otherNames>Ashby EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>5a9d236aa9bbc1.15912868</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B76FC4AF-BEC2-4467-830A-C281F2C81EC9</gtr:id><gtr:title>Renin-angiotensin system inhibitors and risk of fractures: a prospective cohort study and meta-analysis of published observational cohort studies.</gtr:title><gtr:parentPublicationTitle>European journal of epidemiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/8fbda2f0b84566eec04bf63cde9ad5b6"><gtr:id>8fbda2f0b84566eec04bf63cde9ad5b6</gtr:id><gtr:otherNames>Kunutsor SK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0393-2990</gtr:issn><gtr:outcomeId>5a9d236a26e1a0.25519348</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>933719BA-A416-42A6-BD01-F53E29D70ACB</gtr:id><gtr:title>The Rationale and Design of the Reducing Pathology in Alzheimer's Disease through Angiotensin TaRgeting (RADAR) Trial.</gtr:title><gtr:parentPublicationTitle>Journal of Alzheimer's disease : JAD</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/c21f6f23ff33b605f2f34c945d433ecd"><gtr:id>c21f6f23ff33b605f2f34c945d433ecd</gtr:id><gtr:otherNames>Kehoe PG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1387-2877</gtr:issn><gtr:outcomeId>5a9d2369c3d6e5.95593177</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MC_PC_13088</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>7135039D-2DB0-4D41-87B3-FA1C8D38E133</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>6.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>